# Capivasertib treatment associated with hypermetabolism of the spleen

## TL;DR

This paper reports the first cases of splenic hypermetabolism in patients treated with capivasertib for cancer, observed via PET/CT scans.

## Contribution

First documented instances of splenic hypermetabolism associated with capivasertib treatment.

## Key findings

- Two metastatic breast cancer patients showed splenic hypermetabolism on [18F]-FDG PET/CT after capivasertib treatment.
- This phenomenon may be a treatment-related side effect of capivasertib.
- Radiologists should consider this finding when interpreting PET/CT scans in patients on capivasertib.

## Abstract

Capivasertib has emerged as a promising treatment for advanced breast and prostate cancer. Here, we report two cases of metastatic breast cancer patients who developed splenic hypermetabolism on [18 F]-FDG PET/CT following treatment with capivasertib. To our knowledge, these are the first documented instances of this treatment-related phenomenon. Although the mechanism behind this side effect remains unclear, these cases highlight an important imaging phenomenon that radiologists should consider when interpreting [18 F]-FDG PET/CT scans in patients treated with capivasertib.